Statistics indicate that type 2 diabetes (T2D) affects approximately 14% of the global population. This is significant ...
A UC San Francisco analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new ...
A new class of drug for type 2 diabetes could save thousands of lives each year, a study has found. Researchers described the once-daily SGLT-2 inhibitor tablets as working “very well” for a wide ...
The new type 2 diabetes treatment algorithm consensus statement from the American Association of Clinical Endocrinologists (AACE), running to 48 pages, has been published online and is available for ...
A UCSF analysis has found that the newer generation of much more effective diabetes medications are reaching only a fraction of the patients who are recommended to take them based on new guidelines.
Electronic health records used to bridge gap on benefits of SGLT-2 inhibitors for type 2 diabetesDiabetes drugs that may soon ...
When it comes to kidney and cardiovascular outcomes, there is no significant difference between treatment with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results